Stryker Launches Next-Generation Syndesmotic Fixation Device, Synchfix EVT
Portage, Michigan – February 25, 2026 – Stryker, a global leader in medical technology, today announced the launch of Synchfix™ EVT, a fresh flexible syndesmotic fixation device designed to simplify surgical procedures for ankle stabilization. The device aims to improve outcomes for patients suffering from syndesmotic disruptions, injuries often associated with sports trauma and ankle fractures. This launch expands Stryker’s portfolio of solutions for foot and ankle surgeons, offering a new option for both adult and adolescent patients.
Syndesmotic injuries, affecting the ligaments that connect the tibia and fibula bones in the ankle, can significantly impact a patient’s mobility and recovery. Traditional fixation methods can be complex, prompting Stryker to develop Synchfix EVT with a focus on streamlined surgical deployment and enhanced patient care. The device builds upon the foundation of the existing Synchfix platform, incorporating design enhancements intended to reduce procedural complexity compared to previous iterations.
Elevated Design and Surgical Technique
Synchfix EVT distinguishes itself through several key features designed to improve the surgical experience. According to Stryker, the device provides a seamless user experience with an ergonomic handle and a low-profile titanium medial implant. A significant innovation is the integration of suture tensioning handles within the implant instrumentation, simplifying the fixation process. The device also features a handle design enabling one-handed surgical implant deployment, potentially reducing operating time and improving surgical precision.
“Stryker is dedicated to helping foot and ankle surgeons treat their patients more efficiently while enhancing patient care and the overall healthcare experience,” said Adam Jacobs, vice president and general manager of Stryker’s Foot & Ankle business, in a company press release. “Synchfix EVT reflects our commitment to delivering next-generation solutions in soft tissue by designing technologies that help surgeons work more efficiently while keeping patient care and safety at the center.”
Expanding Treatment Options for Adolescents
A particularly noteworthy aspect of Synchfix EVT is its clearance for use in adolescent patients. The device is the first ankle syndesmotic flexible fixation device on the market with this indication, addressing a previously unmet require in pediatric orthopedic care. This expanded applicability allows surgeons to offer a flexible fixation solution to a younger patient population experiencing syndesmotic injuries. The device is intended for soft tissue and bone fixation for ankle syndesmosis disruptions with or without ankle fractures and as an adjunct in connection with hardware for ankle fractures such as Weber B, Weber C and Maisonneuve in both adult and adolescent populations.
The Synchfix EVT system is a sterile, single-use implant/instrument kit. It includes a Synchfix EVT inserter with implant construct, guide wire, and both solid and cannulated drills. The system’s knotless suture design aims to provide a low-profile construct, eliminating knot tying and potential soft tissue irritation. Engineered to eliminate knot-stacking, the device seeks to further minimize complications and optimize healing.
Stryker’s Continued Innovation in Foot and Ankle Surgery
The launch of Synchfix EVT underscores Stryker’s ongoing commitment to innovation in the field of foot and ankle surgery. The company is showcasing the device at the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference, offering demonstrations to highlight its features and benefits. These demonstrations emphasize the sterile, single-use, knotless, and flexible suture-button system designed for stabilizing syndesmotic ankle injuries.
This launch follows a strong financial performance for Stryker, with the company reporting an 11.2% increase in revenue for 2025, driven in part by growth within its vascular segment, as reported on February 24, 2026, by Medical Device Network. Stryker’s 2025 financial results demonstrate the company’s continued investment in medical technology and its commitment to delivering innovative solutions to healthcare providers.
What is Syndesmotic Fixation?
Syndesmotic fixation refers to the surgical repair of the ligaments that connect the tibia and fibula bones at the ankle joint. These ligaments are crucial for maintaining ankle stability, and injuries to these ligaments – often caused by high-energy trauma or sports-related incidents – can lead to chronic pain and instability. Flexible fixation, as offered by Synchfix EVT, allows for some natural ankle movement during the healing process, potentially promoting better functional outcomes. Traditional rigid fixation methods, while effective, can sometimes limit range of motion.
The choice between flexible and rigid fixation depends on the severity of the injury, the patient’s activity level, and the surgeon’s preference. Synchfix EVT aims to provide surgeons with another valuable tool in their arsenal for treating these complex injuries.
Stryker’s Synchfix EVT represents a significant advancement in syndesmotic fixation technology, offering a streamlined surgical technique, improved patient safety features, and expanded treatment options for both adult and adolescent populations. The device’s innovative design and commitment to patient care position it as a promising solution for ankle stabilization.
The company will continue to gather clinical data and feedback from surgeons as Synchfix EVT is adopted into clinical practice. Further updates on the device’s performance and long-term outcomes are expected to be presented at future medical conferences.
Looking ahead, Stryker plans to continue its research and development efforts in the field of foot and ankle surgery, seeking to address unmet clinical needs and improve patient outcomes. The company’s dedication to innovation and collaboration with surgeons will undoubtedly play a key role in shaping the future of ankle injury treatment.
What are your thoughts on this new technology? Share your comments below, and please share this article with your colleagues.